Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients an...
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Te...
One Retrospective Cohort, One Prospective Cohort, in Total of ~2,400 Cancer Patients and Non-cancer...
Two Sample Types, Three Different Platforms, Five Independent Cohorts of ~10,000 Cancer Patients an...
OncoSeek® is a revolutionary multi-cancer early detection (MCED) test developed by SeekIn and empow...
First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNews...
First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 ...
SeekInClarity is a CE-IVD Mark, cost-effective, blood-based pan-cancer/pan-indication treatment res...
The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specifici...
This Blood-based Multi-Cancer Early Detection Test Combines Protein Tumor Markers And Artificial In...
First-of-its-Kind blood-based pan-cancer treatment response monitoring test SHENZHEN, China, May 25...
First-of-its-Kind Molecular Karyotyping Test SHENZHEN, China, April 7, 2022 /PRNewswire/ -- SeekIn ...
SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early d...